ARS Pharma and ALK co-promote neffy nasal spray to up to 9,000 U.S. pediatricians

ARS Pharmaceuticals, Inc.

Co-promotion agreement with ALK-Abelló, Inc. for neffy (epinephrine nasal spray) targeting pediatricians and other prescribers.
ALK starts promotion activities May 2025, must meet ramp-up milestones and minimum detail requirements; non-compete on injectable epinephrine.
ARS books all U.S. sales; ALK receives base fee (first-year deferred) and performance bonuses from year 2: 30% of net sales above preset market share thresholds.
Agreement expires after 4 years; termination provisions include for convenience (with fee) and change of control (mid-seven to low eight-digit fee).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.